文章核心观点 - 公司宣布完成急性缺血性卒中患者的THUNDER临床研究入组 [1][2] - 公司的Thunderbolt吸引管技术可以更快更彻底地清除大脑中的血栓 [2] - THUNDER研究将提供评估Thunderbolt技术的数据,预示着卒中治疗进入新时代 [2] 公司概况 - 公司是全球领先的血栓切除公司,专注于开发创新技术应对缺血性卒中、肺栓塞和急性肢体缺血等医疗状况 [4] - 公司的产品组合包括计算机辅助真空血栓切除(CAVT)技术,可以快速、安全、简单地从头到脚清除血栓 [4] - 公司的产品应用于100多个国家的医疗机构,致力于改善患者的预后和生活质量 [4] THUNDER临床研究 - THUNDER研究是一项多中心单臂研究,评估急性缺血性卒中患者接受机械血栓切除术的疗效 [3] - 主要疗效终点包括手术后立即恢复受阻血管灌注 [3]

Penumbra, Inc. (PEN) is likely to grow in the coming quarters, backed by the strength exhibited in the Thrombectomy business. The company's robust portfolio expansion looks promising. However, the impact of forex woes is a headwind. Competitive disadvantages also add to the worry. In the past year, this Zacks Rank #3 (Hold) company has lost 16.2% against the industry's 17.8% growth and the S&P 500's 30.4% rise. The global healthcare provider company has a market capitalization of $8.67 billion. PEN beat on ...

ALAMEDA, Calif., Oct. 2, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024 at 4:30 PM Eastern Time. A press release with third quarter 2024 financial results will be issued after market close that day. Webcast & Conference Call Information The conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 5872954), or the w ...

The company might just be the right kind of business operating at the right time in history. Veteran medical device maker Penumbra (PEN 4.55%) got a shot of good news on Wednesday. An analyst initiated coverage of the company's stock with a rather bullish review, and investors took this to heart. Collectively, they pushed Penumbra's share price up by almost 5% on a day when the S&P 500 index performed sluggishly with a 0.3% decline. Initiated with a buy recommendation Just after market close on Tuesday, Sti ...

Alameda, CA-based Penumbra, Inc. (PEN) has secured the CE Mark in Europe for its newest computerassisted vacuum thrombectomy (CAVT) technologies, Lightning Flash 2.0 and Lightning Bolt 7. Lightning Flash 2.0 is the most advanced mechanical thrombectomy system available to address venous and pulmonary thrombus while the Lightning Bolt 7 stands out as the most powerful arterial thrombectomy system in the market. The latest innovations further enhance the company's neuro and vascular portfolios. Likely Trend o ...

A month has gone by since the last earnings report for Penumbra (PEN) . Shares have added about 20% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Penumbra due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Penumbra Q2 Earnings Miss, Gross Margin Contracts Penumbra ...

ALAMEDA, Calif., Aug. 27, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 10, 2024. Event: Baird Global Healthcare Conference Date: Tuesday, September 10, 2024 Time: 9:05am ET/6:05am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on t ...

ALAMEDA, Calif., Aug. 21, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Wells Fargo Healthcare Conference on Wednesday, September 4, 2024. Event: Wells Fargo Healthcare Conference Date: Wednesday, September 4, 2024 Time: 2:15pm ET/11:15am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on ...

asikkk/iStock via Getty Images Penumbra (NYSE:PEN) is a leader in the field of medical technology, with both vascular and neurological devices making a big splash in the improvement of care. The stock has been volatile over the past few years, with a peak of $340 in late June 2023 making way to a low of $148 recently. Now the shares are intriguing at $191/share as excitement for the new Lightning Flash and Thunderbolt are continuing to help drive revenue growth. They are both computed assisted vacuum thromb ...

To Include $100 Million Accelerated Share Repurchase ALAMEDA, Calif., Aug. 13, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today announced that its Board of Directors approved on August 5, 2024 a share repurchase authorization in the amount of up to $200 million, allowing Penumbra to repurchase its common stock from time to time at such prices as it deems appropriate through open market purchases, block transactions, privately negotiated transactions, including ...